Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Biological Molecules via aptamer refers to a broad class of molecular entities, including proteins, small molecules, and cell-surface receptors, that are specifically recognized and bound by aptamers. Aptamers are short, single-stranded DNA, RNA, or peptide sequences that fold into complex three-dimensional structures, allowing them to function as chemical antibodies. This targeting modality is used in therapeutics to inhibit the function of disease-associated proteins, such as vascular endothelial growth factor (VEGF) in age-related macular degeneration or complement component 5 (C5) in geographic atrophy. Because this term describes a diverse group of targets rather than a single biological entity, it is considered a categorical classification rather than a specific therapeutic target. Aptamer-based targeting offers advantages such as low immunogenicity, high stability, and ease of chemical modification for diagnostic and therapeutic applications.
Aptamers bind to their target molecules with high affinity and specificity, typically acting as antagonists to block protein-protein or protein-ligand interactions, or as delivery vehicles for other therapeutic agents.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Biological Molecules via aptamer.